Pharma Stock engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharma Ingredients in focus upon signing pact with Takeda Pharmaceutical Company Limited.
With a market capitalization of Rs. 3,54,085 Crores, the shares of Sun Pharmaceuticals Industries Limited were trading at Rs. 1,475.80 per equity share, up 0.48 percent from its previous day’s close price of Rs. 1,470.45.
Sun Pharmaceuticals Industries Limited has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name “Voltapraz”
Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders like Gastroesophageal Reflux Disease, etc.
In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of healing of all grades of Erosive esophagitis and relief of heartburn associated with Erosive esophagitis and in combination with amoxicillin and clarithromycin or amoxicillin alone for the
treatment of Helicobacter pylori (H. pylori) infection in adults. The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders.
Gastroesophageal Reflux Disease (GERD) is common in India irrespective of geographical or rural/urban location. Prevalence of GERD in Indian population ranges from 5 percent to 28.5 percent. Risk factors for GERD include age, body mass index (BMI), non-vegetarian diet, tea/coffee intake, tobacco, and alcohol consumption
Sun Pharmaceutical Industries Limited is one of the largest pharmaceutical companies in India the fourth largest specialty generic company in the world, it is engaged in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and Active Pharma Ingredients.
Sun Pharmaceutical Industries Limited has Manufacturing capabilities across injectables, sprays, ointments, creams, liquids, tablets and capsules.
It has a diversified revenue base with India Branded Formulations contributing 32 percent, US Formualtions 31 percent, Emerging Markets 18 percent, API & Others 5 percent and 14 percent Rest of the World.
Its Revenue from operations grew by 10.14 percent from Rs. 10,725 Crores in Q4FY23 to Rs. 11,813 Crores in Q4FY24, accompanied by profits of Rs. 2,016.78 Crores to Rs. 2,666.59 Crores.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
